Drug intelligence / Profile preview

deltorphin II

Development stage
Unknown
Modality
Peptides
01

Overview

Deltorphin II (also known as deltorphin B) is a naturally occurring heptapeptide originally isolated from the skin secretions of South American tree frogs of the genus *Phyllomedusa* (such as *Phyllomedusa bicolor*). It is one of the most potent and highly selective agonists of the delta-opioid receptor (DOR) known, exhibiting several orders of magnitude higher selectivity for delta-opioid receptors over mu- and kappa-opioid receptors. Structurally, it features a D-alanine residue at position 2, which confers resistance to enzymatic degradation and enhances its biostability. Deltorphin II is widely utilized as a pharmacological research tool to study the physiological roles of delta-opioid receptors, including their involvement in antinociception, neuropathic pain, cardiovascular regulation, and metabolic homeostasis.

Other names
[D-Ala2, Glu4]deltorphin II[D-Ala2]-deltorphin IIDADELT IITyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH-2Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH 2deltorphin B
02

Targets

DOR (Opioid Receptor Delta 1)MAPK3 (Mitogen-activated protein kinase 1)KATP channel (ATP-sensitive potassium channel)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PRKCD (Protein kinase C delta)

Beyond the preview

Go deeper on deltorphin II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on deltorphin II.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call